P789: EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN (IPTA) MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH THE ANTI-C5 MONOCLONAL ANTIBODY (MAB) TESIDOLUMAB (TESI)
Kiyoshi Ando,
Laimonas Griškevičius,
Takayuki Ikezoe,
Yoshikazu Ito,
Masayoshi Masuko,
Yasutaka Ueda,
Morten Bagger,
Rambabu Danekula,
Izabela Rozenberg,
Guido Junge,
Jiri Mayer
Affiliations
Kiyoshi Ando
1 Tokai University School of Medicine, Isehara, Japan,
Laimonas Griškevičius
2 Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania,
Takayuki Ikezoe
3 Fukushima Medical University Hospital, Fukushima, Japan,
Yoshikazu Ito
4 Tokyo Medical University Hospital, Tokyo, Japan,
Masayoshi Masuko
5 Niigata University Medical and Dental Hospital, Niigata, Japan,
Yasutaka Ueda
6 Osaka University Hospital, Osaka, Japan,
Morten Bagger
7 Novartis Institutes for Biomedical Research, Basel, Switzerland,
Rambabu Danekula
7 Novartis Institutes for Biomedical Research, Basel, Switzerland,
Izabela Rozenberg
7 Novartis Institutes for Biomedical Research, Basel, Switzerland,
Guido Junge
7 Novartis Institutes for Biomedical Research, Basel, Switzerland,
Jiri Mayer
8 University Hospital Brno and Masaryk University, Brno, Czech Republic
